Virupaksha Organics is an API and finished-dose manufacturer based in India. It holds 18 active US drug master files and 6 valid CEPs across a filed portfolio of 11 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 7 February 2025 as VAI. Customs aggregates show $15.6M of exports covering 280 molecules to 55 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hyderabad, India | 3018360272 |
| Sangareddy, India | 3008154209 |
| Gaddipotharam, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Citalopram | EDQM, US FDA | 3 |
| Escitalopram | EDQM, US FDA | 3 |
| Fexofenadine | SFDA (Saudi Arabia), US FDA | 3 |
| Fluconazole | EDQM, US FDA | 3 |
| Tramadol | EDQM, US FDA | 3 |
| Bilastine | US FDA | 2 |
| Crisaborole | US FDA | 2 |
| Dextromethorphan | US FDA | 2 |
| Efinaconazole | US FDA | 2 |
| Fexofenadine Hydrochloride | EDQM | 1 |
| Tapentadol | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | 4 | None |
| US FDA | None | 1 |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $3.4M | 25 |
| 2025 | Not reported | $15.6M | 55 |
| 2024 | Not reported | $19.1M | 53 |
| 2023 | Not reported | $31.6M | 45 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Virupaksha Organics comes back tiered against every other supplier able to file there.
Start for free